Allocation of Opportunities to Participate in Clinical Trials during the Covid-19 Pandemic and Other Public Health Emergencies

Kayte Spector-Bagdady; Holly Fernandez Lynch; Barbara E. Bierer; Luke Gelinas; Sara Chandros Hull; David Magnus; Michelle N. Meyer; Richard R. Sharp; Jeremy Sugarman; Benjamin S. Wilfond; Ruqaiijah Yearby; Seema Mohapatra

doi:10.1002/hast.1297

Allocation of Opportunities to Participate in Clinical Trials during the Covid-19 Pandemic and Other Public Health Emergencies

Kayte Spector-Bagdady, Holly Fernandez Lynch, Barbara E. Bierer, Luke Gelinas, Sara Chandros Hull, David Magnus, Michelle N. Meyer, Richard R. Sharp, Jeremy Sugarman, Benjamin S. Wilfond, Ruqaiijah Yearby, Seema Mohapatra

Academic Centers

Research output: Contribution to journal › Article › peer-review

Abstract

Covid-19 raised many novel ethical issues including regarding the allocation of opportunities to participate in clinical trials during a public health emergency. In this article, we explore how hospitals that have a scarcity of trial opportunities, either overall or in a specific trial, can equitably allocate those opportunities in the context of an urgent medical need with limited therapeutic interventions. We assess the three main approaches to allocating trial opportunities discussed in the literature: patient choice, physician referral, and randomization/lottery. As, we argue, none of the three typical approaches are ethically ideal for allocating trial opportunities in the pandemic context, many hospitals have instead implemented hybrid solutions. We offer practical guidance to support those continuing to face these challenges, and we analyze options for the future.

Original language	English (US)
Pages (from-to)	51-58
Number of pages	8
Journal	Hastings Center Report
Volume	52
Issue number	1
DOIs	https://doi.org/10.1002/hast.1297
State	Published - Jan 1 2022

Keywords

Covid-19
clinical trials
public health
research ethics
trial recruitment

ASJC Scopus subject areas

Health(social science)
Philosophy
Health Policy
Issues, ethics and legal aspects

Access to Document

10.1002/hast.1297

Cite this

Spector-Bagdady, K., Lynch, H. F., Bierer, B. E., Gelinas, L., Hull, S. C., Magnus, D., Meyer, M. N., Sharp, R. R., Sugarman, J., Wilfond, B. S., Yearby, R., & Mohapatra, S. (2022). Allocation of Opportunities to Participate in Clinical Trials during the Covid-19 Pandemic and Other Public Health Emergencies. Hastings Center Report, 52(1), 51-58. https://doi.org/10.1002/hast.1297

@article{d74237f44182495ebcf9e2e55046d9e5,

title = "Allocation of Opportunities to Participate in Clinical Trials during the Covid-19 Pandemic and Other Public Health Emergencies",

abstract = "Covid-19 raised many novel ethical issues including regarding the allocation of opportunities to participate in clinical trials during a public health emergency. In this article, we explore how hospitals that have a scarcity of trial opportunities, either overall or in a specific trial, can equitably allocate those opportunities in the context of an urgent medical need with limited therapeutic interventions. We assess the three main approaches to allocating trial opportunities discussed in the literature: patient choice, physician referral, and randomization/lottery. As, we argue, none of the three typical approaches are ethically ideal for allocating trial opportunities in the pandemic context, many hospitals have instead implemented hybrid solutions. We offer practical guidance to support those continuing to face these challenges, and we analyze options for the future.",

keywords = "Covid-19, clinical trials, public health, research ethics, trial recruitment",

author = "Kayte Spector-Bagdady and Lynch, {Holly Fernandez} and Bierer, {Barbara E.} and Luke Gelinas and Hull, {Sara Chandros} and David Magnus and Meyer, {Michelle N.} and Sharp, {Richard R.} and Jeremy Sugarman and Wilfond, {Benjamin S.} and Ruqaiijah Yearby and Seema Mohapatra",

note = "Publisher Copyright: {\textcopyright} 2022 The Hastings Center",

year = "2022",

month = jan,

day = "1",

doi = "10.1002/hast.1297",

language = "English (US)",

volume = "52",

pages = "51--58",

journal = "Hastings Center Report",

issn = "0093-0334",

publisher = "Hastings Center",

number = "1",

}

TY - JOUR

T1 - Allocation of Opportunities to Participate in Clinical Trials during the Covid-19 Pandemic and Other Public Health Emergencies

AU - Spector-Bagdady, Kayte

AU - Lynch, Holly Fernandez

AU - Bierer, Barbara E.

AU - Gelinas, Luke

AU - Hull, Sara Chandros

AU - Magnus, David

AU - Meyer, Michelle N.

AU - Sharp, Richard R.

AU - Sugarman, Jeremy

AU - Wilfond, Benjamin S.

AU - Yearby, Ruqaiijah

AU - Mohapatra, Seema

PY - 2022/1/1

Y1 - 2022/1/1

N2 - Covid-19 raised many novel ethical issues including regarding the allocation of opportunities to participate in clinical trials during a public health emergency. In this article, we explore how hospitals that have a scarcity of trial opportunities, either overall or in a specific trial, can equitably allocate those opportunities in the context of an urgent medical need with limited therapeutic interventions. We assess the three main approaches to allocating trial opportunities discussed in the literature: patient choice, physician referral, and randomization/lottery. As, we argue, none of the three typical approaches are ethically ideal for allocating trial opportunities in the pandemic context, many hospitals have instead implemented hybrid solutions. We offer practical guidance to support those continuing to face these challenges, and we analyze options for the future.

AB - Covid-19 raised many novel ethical issues including regarding the allocation of opportunities to participate in clinical trials during a public health emergency. In this article, we explore how hospitals that have a scarcity of trial opportunities, either overall or in a specific trial, can equitably allocate those opportunities in the context of an urgent medical need with limited therapeutic interventions. We assess the three main approaches to allocating trial opportunities discussed in the literature: patient choice, physician referral, and randomization/lottery. As, we argue, none of the three typical approaches are ethically ideal for allocating trial opportunities in the pandemic context, many hospitals have instead implemented hybrid solutions. We offer practical guidance to support those continuing to face these challenges, and we analyze options for the future.

KW - Covid-19

KW - clinical trials

KW - public health

KW - research ethics

KW - trial recruitment

UR - http://www.scopus.com/inward/record.url?scp=85121400343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85121400343&partnerID=8YFLogxK

U2 - 10.1002/hast.1297

DO - 10.1002/hast.1297

M3 - Article

C2 - 34908169

AN - SCOPUS:85121400343

SN - 0093-0334

VL - 52

SP - 51

EP - 58

JO - Hastings Center Report

JF - Hastings Center Report

IS - 1

ER -

Allocation of Opportunities to Participate in Clinical Trials during the Covid-19 Pandemic and Other Public Health Emergencies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this